

23 February 2016

ASX Code: MXC

Investor Report by the Next Bio Tech

MGC Pharmaceuticals Ltd (ASX:MXC or “the Company”) is pleased to announce the publication of an article by Next Bio Tech on the Company’s imminent first revenues from MXC’s CBD cosmetics line and operations.

This report is a note by Next Bio Tech, which is available to be viewed via a link on the Company’s website <http://mgcpharma.com.au/#MediaNews>

-Ends-

For further information please contact:

Media Enquiries

Asher Moses
Director
Media and Capital Partners
+61 438 008 616
Asher.moses@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MGC

MGC is EU based specialist medical and cosmetic cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabinoid resin extract (“CBD”) to the growing European cosmetics and medical markets.